BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rahimi F, Bezmin Abadi AT. The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic. Int J Surg 2022;99:106261. [PMID: 35167986 DOI: 10.1016/j.ijsu.2022.106261] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Hamad M, AlKhamach DMH, Alsayadi LM, Sarhan SA, Saeed BQ, Sokovic M, Ben Hadda T, Soliman SSM. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. Viral Immunol 2023;36:83-100. [PMID: 36695729 DOI: 10.1089/vim.2022.0122] [Reference Citation Analysis]
2 Doke PP, Mhaske ST, Oka G, Kulkarni R, Muley V, Mishra AC, Arankalle VA. SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India. Front Public Health 2022;10:1040012. [PMID: 36711329 DOI: 10.3389/fpubh.2022.1040012] [Reference Citation Analysis]
3 Liu L, Xie S, Li C, Su L, Zhu C. Effect of nasal irrigation in adults infected with Omicron variant of COVID-19: A quasi-experimental study. Front Public Health 2022;10:1046112. [PMID: 36699894 DOI: 10.3389/fpubh.2022.1046112] [Reference Citation Analysis]
4 Truszkowska A, Zino L, Butail S, Caroppo E, Jiang ZP, Rizzo A, Porfiri M. Exploring a COVID-19 Endemic Scenario: High-Resolution Agent-Based Modeling of Multiple Variants. Adv Theory Simul 2023;6:2200481. [PMID: 36718198 DOI: 10.1002/adts.202200481] [Reference Citation Analysis]
5 Safdar S, Ngonghala CN, Gumel AB. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Math Biosci Eng 2023;20:179-212. [PMID: 36650762 DOI: 10.3934/mbe.2023009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang J, Liu Y, Lei W, Shen J, Lu J, Tao T, Cao X, Yang Z, Huang J, Shi C. Oral Liushen pill for patients with COVID-19: A prospective randomized controlled trial. Pulm Circ 2023;13:e12187. [PMID: 36733313 DOI: 10.1002/pul2.12187] [Reference Citation Analysis]
7 Akowuah KA, Akuffo RA, Boateng AT, Asigbee TW, Bonney JHK, Lamptey H, Adusei-Poku MA, Obodai E, Asante IA, Adjei S, Aboagye JO, Adu-Amankwah S, Partey FD, Kyei GB, Ampofo WK, Odoom JK, Bonney EY. SARS-CoV-2 infections among asymptomatic individuals contributed to COVID-19 cases: A cross-sectional study among prospective air travelers from Ghana. Front Public Health 2022;10:1035763. [PMID: 36589973 DOI: 10.3389/fpubh.2022.1035763] [Reference Citation Analysis]
8 Varghese MS, Strom JB, Kannam JP, Fostello SE, Riley MF, Manning WJ. Impact of the COVID-19 pandemic on cardiology fellow echocardiography education at a large academic center. BMC Med Educ 2022;22:863. [DOI: 10.1186/s12909-022-03880-z] [Reference Citation Analysis]
9 Ramadan Abdelmoez Farahat, Abdelaziz Abdelaal, Tungki Pratama Umar, Amro A. El-Sakka, Amira Yasmine Benmelouka, Khaled Albakri, Iftikhar Ali, Tareq Al-Ahdal, Basel Abdelazeem, Ranjit Sah, Alfonso J. Rodriguez-Morales. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends. Infez Med 2022;30. [PMID: 36482957 DOI: 10.53854/liim-3004-2] [Reference Citation Analysis]
10 Chia TRT, Young BE, Chia PY. The Omicron-transformer: Rise of the subvariants in the age of vaccines. Ann Acad Med Singap 2022;51:712-729. [DOI: 10.47102/annals-acadmedsg.2022294] [Reference Citation Analysis]
11 Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xu R, Wang W, Zhang W. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it? Front Public Health 2022;10:1039123. [PMID: 36504951 DOI: 10.3389/fpubh.2022.1039123] [Reference Citation Analysis]
13 Xiang T, Wang J, Zheng X. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. Virol Sin 2022:S1995-820X(22)00191-2. [PMID: 36427646 DOI: 10.1016/j.virs.2022.11.007] [Reference Citation Analysis]
14 Yin S, Mei S, Li Z, Xu Z, Wu Y, Chen X, Liu D, Niu M, Li J. Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1037993] [Reference Citation Analysis]
15 Bedada FB, Gorfu G, Teng S, Neita ME. Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.917201] [Reference Citation Analysis]
16 Błaszczuk A, Michalski A, Sikora D, Malm M, Drop B, Polz-Dacewicz M. Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant. Vaccines (Basel) 2022;10:1728. [PMID: 36298593 DOI: 10.3390/vaccines10101728] [Reference Citation Analysis]
17 Islam MR, Shahriar M, Bhuiyan MA. The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health. Health Sci Rep 2022;5:e884. [PMID: 36254237 DOI: 10.1002/hsr2.884] [Reference Citation Analysis]
18 Shi C, Liu Y, Lei W, Shen J, Lu J, Tao T, Cao X, Yang Z, Huang J, Zhang J. Oral Liushen Pill for Patients with Covid-19 : A prospective, randomized, controlled trial.. [DOI: 10.21203/rs.3.rs-1957687/v1] [Reference Citation Analysis]
19 Nowakowski A"CH. Same Old New Normal: The Ableist Fallacy of “Post-Pandemic” Work. SI 2022;11. [DOI: 10.17645/si.v11i1.5647] [Reference Citation Analysis]
20 Yan VKC BPharm, Wan EYF PhD, Ye X MSc, Mok AHY MClinPharm, Lai FTT PhD, Chui CSL PhD, Li X PhD, Wong CKH PhD, Li PH MBBS, Ma T PhD, Qin S PhD, Wong VKC MPhil, Tsang TC MBBS, Tsui SH MBBS, Chui WCM MSc, Cowling BJ PhD, Leung GM MD, Lau CS MD, Wong ICK PhD, Chan EWY PhD. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. Emerg Microbes Infect 2022;:1-48. [PMID: 35980089 DOI: 10.1080/22221751.2022.2114854] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ren L, Xu Y, Ning L, Pan X, Li Y, Zhao Q, Pang B, Huang J, Deng K, Zhang Y. TCM2COVID: A resource of anti‐COVID‐19 traditional Chinese medicine with effects and mechanisms. iMeta. [DOI: 10.1002/imt2.42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li T, Luo KQ. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. Int J Biol Sci 2022;18:4642-7. [PMID: 35874950 DOI: 10.7150/ijbs.72424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Aoki A, Adachi H, Mori Y, Ito M, Sato K, Okuda K, Sakakibara T, Okamoto Y, Jinno H. Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot Study. Microbiol Spectr 2022;:e0136722. [PMID: 35861527 DOI: 10.1128/spectrum.01367-22] [Reference Citation Analysis]
24 Awan HA, Awan S, Shaikh HS, Swed S, Hasan MM. Emergence of Omicron BA.2.12.1 in Pakistan: What does it mean for the South Asian nation? Annals of Medicine and Surgery 2022;79:103943. [DOI: 10.1016/j.amsu.2022.103943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Stewart JB. Community, Risk Assessment, Prevention and Control: Black American College Student's Information Seeking on COVID-19. Health Info Libr J 2022. [PMID: 35764293 DOI: 10.1111/hir.12442] [Reference Citation Analysis]
26 Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Msomi N, Naidoo Y, Pillay S, Sanko TJ, San JE, Scott L, Singh L, Magini NA, Smith-lawrence P, Stevens W, Dor G, Tshiabuila D, Wolter N, Preiser W, Treurnicht FK, Venter M, Davids M, Chiloane G, Mendes A, Mcintyre C, O’toole A, Ruis C, Peacock TP, Roemer C, Williamson C, Pybus OG, Bhiman J, Glass A, Martin DP, Rambaut A, Gaseitsiwe S, Gottberg AV, de Oliveira T, NGS-SA consortium. Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages.. [DOI: 10.1101/2022.05.01.22274406] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 39.0] [Reference Citation Analysis]
27 Gudina EK, Ali S, Froeschl G. Omicron: A Blessing in Disguise? Front Public Health 2022;10:875022. [DOI: 10.3389/fpubh.2022.875022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yadav S. Stealth omicron-A new substrain in an ongoing pandemic of COVID-19. IJIRM 2022;7:4-5. [DOI: 10.18231/j.ijirm.2022.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Aoki A, Adachi H, Mori Y, Ito M, Sato K, Okuda K, Sakakibara T, Okamoto Y, Jinno H. Discrimination of SARS-CoV-2 Omicron sub-lineages BA.1 and BA.2 using a high-resolution melting-based assay: A pilot study.. [DOI: 10.1101/2022.04.11.487970] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Fu N, Jiang Y, Xu Z, Yang M, Peng C, Deng X, Zhao S, Shen B. The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. Aging Cancer 2022;3:161-8. [PMID: 36718230 DOI: 10.1002/aac2.12056] [Reference Citation Analysis]
31 Chavda VP, Vuppu S, Mishra T, Kamaraj S, Patel AB, Sharma N, Chen ZS. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep 2022;74:1120-48. [PMID: 36214969 DOI: 10.1007/s43440-022-00425-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]